317 related articles for article (PubMed ID: 21393611)
1. Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
Cruzado JM; Poveda R; Ibernón M; Díaz M; Fulladosa X; Carrera M; Torras J; Bestard O; Navarro I; Ballarín J; Romero R; Grinyó JM
Nephrol Dial Transplant; 2011 Nov; 26(11):3596-602. PubMed ID: 21393611
[TBL] [Abstract][Full Text] [Related]
2. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
Soleymanian T; Najafi I; Salimi BH; Broomand B
Ren Fail; 2011; 33(6):572-7. PubMed ID: 21663387
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
6. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
7. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
8. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
9. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
11. Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.
Li PK; Kwan BC; Chow KM; Leung CB; Szeto CC
Am J Med; 2013 Feb; 126(2):162-8. PubMed ID: 23331443
[TBL] [Abstract][Full Text] [Related]
12. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
13. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
Liew A; Chiang GS; Vathsala A
Transpl Int; 2009 Mar; 22(3):313-22. PubMed ID: 19054382
[TBL] [Abstract][Full Text] [Related]
15. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study.
Pankewycz O; Leca N; Kohli R; Weber-Shrikant E; Said M; Alnimri M; Feng L; Patel S; Laftavi MR
Transplant Proc; 2011 Mar; 43(2):519-23. PubMed ID: 21440749
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
[TBL] [Abstract][Full Text] [Related]
17. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification).
Edström Halling S; Söderberg MP; Berg UB
Nephrol Dial Transplant; 2012 Feb; 27(2):715-22. PubMed ID: 21750154
[TBL] [Abstract][Full Text] [Related]
18. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
[TBL] [Abstract][Full Text] [Related]
19. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.
Eitner F; Ackermann D; Hilgers RD; Floege J
J Nephrol; 2008; 21(3):284-9. PubMed ID: 18587715
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
